16 January 2026
: Case report 
A 17-Year-Old Male Adolescent With Refractory Crohn’s Disease Managed With Upadacitinib and Risankizumab Combination Therapy: A Case Report and Review of Current Evidence
Unusual or unexpected effect of treatment
Mohammad Alhashemi BCDEF 1, Mohammad Shehab
A 1*
DOI: 10.12659/AJCR.950174
Am J Case Rep 2026; 27:e950174
Figure 3 Images taken after the start of upadacitinib and risankizumab; quiescent disease, with Simple Endoscopic Score for Crohn’s disease score <4: (A) the rectum; (B) the ascending colon; (C) the terminal ileum; and (D) the cecum.